Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H34N4O5 |
Molecular Weight | 494.5827 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1([C@@H](C)CC)N([C@@H](C(=O)N2CCOCC2)C3=COC(C)=N3)C(=O)[C@H](NC1=O)C4CC5=C(C4)C=CC=C5
InChI
InChIKey=PLVGDGRBPMVYPB-FDUHJNRSSA-N
InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
Molecular Formula | C27H34N4O5 |
Molecular Weight | 494.5827 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Retosiban is a small molecule oxytocin receptor antagonist that is under evaluation for treatment of premature labor. Retosiban was found to be safe in healthy non-pregnant volunteers in phase I studies. Intravenous retosiban also had good safety and tolerability in phase II studies and was suggested to prolong pregnancies in women with preterm labor. Phase III studies have been conducted to demonstrate the efficacy of retosiban to prolong pregnancy and improve neonatal outcomes, and compare effects with a similar drug atosiban, but these studies were terminated in 2018 (not due to adverse events).
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:47 GMT 2023
by
admin
on
Fri Dec 15 15:25:47 GMT 2023
|
Record UNII |
GIE06H28OX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98292
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11340891
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
DTXSID00231559
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
SUB181222
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
GIE06H28OX
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
Retosiban
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
TT-30
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
820957-38-8
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL429736
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
100000166887
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
DB11818
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
8924
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY | |||
|
C76681
Created by
admin on Fri Dec 15 15:25:47 GMT 2023 , Edited by admin on Fri Dec 15 15:25:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|